Sugisawa, Norihiko http://orcid.org/0000-0003-1887-7268
Higuchi, Takashi
Han, Qinghong
Hozumi, Chihiro
Yamamoto, Jun
Tashiro, Yoshihiko
Nishino, Hiroto
Kawaguchi, Kei
Bouvet, Michael
Murata, Takuya
Unno, Michiaki
Hoffman, Robert M.
Funding for this research was provided by:
Robert M. Hoffman Foundation for Cancer Research
Article History
Received: 19 September 2020
Accepted: 16 March 2021
First Online: 25 March 2021
Declarations
:
: The authors declare that there are no potential conflicts of interest. AntiCancer, Inc. uses PDOX mouse models for contract research. QH is an employee of AntiCancer, Inc. NS, TH, JY, YT, HN, and RMH are or were unsalaried associates of AntiCancer, Inc.
: The mouse experiments were carried out under an AntiCancer, Inc. Institutional Animal Care and Use Committee (IACUC) approved protocol using guidelines of the National Institutes of Health Guide for the Care and Use of Animals, under Assurance Number A3873-1.
: Written informed consent was provided by the patient as a part of an approved protocol by the Institutional Review Board (IRB) of Kawasaki Medical School.
: All authors agree with the contents of the present manuscript and for submission to Cancer Chemotherapy and Pharmacology.